Table 1.
Ongoing clinical trials investigating glioma immunologya
| NCT NUMBER | PHASE | TARGET | NAME OF TRIAL | STATUS | PATIENT ENROLLMENT |
|---|---|---|---|---|---|
| NCT02649582 | I/II | DC-vaccine + Chemotherapy | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients | Recruiting | 20 |
| NCT02465268 | II | DC-vaccine (pp65 DC) + Chemotherapy | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme | Recruiting | 175 |
| NCT02208362 | I | Genetically modified T-cell immunotherapy | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | Active, not recruiting | 82 |
| NCT03347097 | I | Genetically modified T-cell immunotherapy | Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme | Active, not recruiting | 40 |
| NCT03696030 | I | HER2-CAR T Cell Therapy | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases | Recruiting | 39 |
| NCT02924038 | I | Peptide Vaccination + CD27 MoAb (IMA950, poly-ICLC + Valilumab) | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Active, not recruiting | 14 |
| NCT04943718 | I | Peptide Vaccination | Personalized Vaccine for Patients With Recurrent Malignant Glioma | Recruiting | 10 |
| NCT03779230 | I/II | Immunocytokine (L19TNF) | Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON) | Active, not recruiting | 20 |
| NCT04729959 | II | IL-6 + PD-L1 Blockade (Tocilizumab, Atezolizumab) + Radiatior | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Suspended (Scheduled Interim Monitoring) | 12 |
| NCT02337686 | II | Anti-PD-1 (Pembrolizumab) | Pembrolizumab in Treating Patients With Recurrent Glioblastoma | Active, not recruiting | 20 |
| NCT04145115 | II | Anti-PD-1 + Anti-CTLA-4 (Nivolumab, Ipilimumab) | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | Recruiting | 37 |
| NCT04817254 | II | Anti-PD-1, Anti-CTLA-4 + Chemotherapy (Nivolumab, Ipilimumab + Temozolomide) | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Recruiting | 48 |
| NCT04606316 | I | Anti-PD-1, Anti-CTLA-4 (Nivolumab, Ipilimumab) + Surgery | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Recruiting | 60 |
| NCT03493932 | I | Anti-PD-1 + Anti-LAG-3 (Nivolumab, BMS-986016) | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | Active, not recruiting | 20 |
| NCT03576612 | I | Anti-PD-1 + Immunostimulator (Nivolumab, GMCI) + Radiation + Chemotherapy | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI) | Active, not recruiting | 36 |
| NCT02022384 | IV | Chemoradiation | Immunophenotyping From Blood of Patients With Malignant Gliomas | Active, not recruiting | 50 |
| NCT04065776 | Interventional | Radiation (Hippocampal-avoidance proton therapy) | Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma | Recruiting | 74 |
| NCT04781764 | IV | Surgical/Tumor Biopsy | The Study of Microglia/Macrophages Involved Dynamic Evolution of Glioma Microenvironment and the Function and Visualization of Targeted Molecules of Glioma | Recruiting | 60 |
| NCT03189420 | IV | Surgical/Tumor Biopsy | Glioma Microenvironment an Exploratory Study | Active, not recruiting | 30 |
| NCT04461938 | Interventional | Surgical/Tumor Biopsy | Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) | Recruiting | 30 |
| NCT04792437 | IV | Surgical/Tumor Biopsy | Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data | Recruiting | 120 |
| NCT04865315 | IV | Surgical/Tumor Biopsy | A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors (HiLoGlio) | Active, not recruiting | 50 |
| NCT01246869 | I | MRI and PET Scan Visualization (18F-FDG, 18F-FMISO, H2O) | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water | Recruiting | 30 |
| NCT05047913 | I | MRI and PET Scan Visualization (18F-FTX) | Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MRI | Recruiting | 20 |
| NCT04309552 | I | PET Scan Visualization (18F-FMISO, 18F-FLT PET) | Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma | Recruiting | 30 |
a
All trials were found on clinicaltrials.gov and were active at time of publication. Trial phases range from I – IV.